Cargando…
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults
Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. V181 is an investigational, live, attenuated, quadrivalent dengue vaccine. In this phase 1 double-blind, placebo-controlled study, the safety, tolerability, and immu...
Autores principales: | Russell, Kevin L., Rupp, Richard E., Morales-Ramirez, Javier O., Diaz-Perez, Clemente, Andrews, Charles P., Lee, Andrew W., Finn, Tyler S., Cox, Kara S., Falk Russell, Amy, Schaller, Margaret M., Martin, Jason C., Hyatt, Donna M., Gozlan-Kelner, Sabrina, Bili, Androniki, Coller, Beth-Ann G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225326/ https://www.ncbi.nlm.nih.gov/pubmed/35290152 http://dx.doi.org/10.1080/21645515.2022.2046960 |
Ejemplares similares
-
636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)
por: Russell, Kevin, et al.
Publicado: (2021) -
Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses
por: Shoushtari, Mohammad, et al.
Publicado: (2022) -
Mechanism through Which Retrocyclin Targets Flavivirus Multiplication
por: Jia, Xiaoying, et al.
Publicado: (2021) -
Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023) -
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023)